Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies.

Autor: Kutkat O; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Moatasim Y; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Al-Karmalawy AA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt., Abulkhair HS; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 11884, Egypt., Gomaa MR; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., El-Taweel AN; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Abo Shama NM; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., GabAllah M; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Mahmoud DB; Pharmaceutics Department, Egyptian Drug Authority, formerly known as National Organization for Drug Control and Research, Giza, 12654, Egypt., Kayali G; Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX, 77030, USA.; Human Link DMCC, Dubai, UAE., Ali MA; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Kandeil A; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt. kandeil_a@hotmail.com., Mostafa A; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt. ahmed_elsayed@daad-alumni.de.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Jul 28; Vol. 12 (1), pp. 12920. Date of Electronic Publication: 2022 Jul 28.
DOI: 10.1038/s41598-022-17082-6
Abstrakt: During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (M pro ) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje